- Rating
- 3
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper proposes JANUS-PEP, a multi-agent framework for designing bifunctional antimicrobial peptides. Starting from a natural-language description of an infection scenario, the system sequentially determines a second therapeutic function, a molecular target, and a structural epitope, and then generates peptide sequences that simultaneously satisfy target binding, antimicrobial activity, and hemolytic safety constraints. The framework contains four modules: planning and generation, diagnosis, redesign, and external physics-based scoring. Through persistent memory, it stores candidate sequences, diagnoses, pre-registered directional predictions, and subsequent scoring results. For targets with an available structural pocket, the system uses the structure-based path and interface energetics; for targets lacking a structural pocket, it uses the sequence-based path and interface confidence.
The authors further perform supervised fine-tuning and GRPO optimization of the Redesigner using a decision corpus constructed from experimental measurements. The corpus is drawn mainly from SKEMPI 2.0, DBAASP, and GRAMPA, with general biomedical tasks also included; the authors report entity-level splits by complex or parent peptide, class balancing, and shortcut audits. The optimized Qwen3-14B achieves a mean accuracy of 73.83% across six tasks, an improvement of 25.64 percentage points over the zero-shot result of the same backbone. For the clinical scenarios listed in Table 2, the system produces at least one passing candidate under the predicted binding, MIC, and HC50 metrics; after re-scoring with external predictors, 73% of candidates still satisfy both activity and safety criteria.
The main value of the paper lies in organizing scenario parsing, candidate redesign, external scoring, and evidence memory into an auditable computational pipeline, and in attempting to train the Redesigner with decision tasks built from experimental measurements. At the same time, the current evidence still comes mainly from computational predictors and an internal benchmark; the paper lacks comparisons with comparable work and does not provide wet-lab validation.
Critical strengths
S1. The problem setting has identifiable novelty: incorporating "inferring a second therapeutic function from a natural-language scenario and resolving it to a target" into the peptide-design pipeline differs from existing AMP multi-objective optimization work (which presets activity/toxicity/novelty objectives) in its inputs and intermediate representations (Page 1-2, Fig. 1).
S2. The experimental design is rich and the workload is substantial; the experiments provide a fairly comprehensive analysis of individual pathways and modules within the agent framework as well as the overall capability of the framework. Breadth of scenario coverage: the 26 scenarios span three major categories—host response, pathogen virulence, and tissue repair—and the targets include both host proteins and microbial proteins (Appendix C, Fig. 9).
Critical weaknesses
W1. There is a lack of external baseline comparisons with comparable work. The comparison in Table 1 is between the same backbone model in "zero-shot" mode and embedded within the framework; there is no head-to-head comparison with any other agent framework (such as MAC-AMP, PABLO, or EASER) or AMP generation model (such as PepTune or AMPGAN v3) under a unified predictor setting. Readers cannot judge whether the JANUS-PEP architecture is superior to existing methods (Page 7, Table 1).
W2. Some claims lack direct experimental support and are not directly tested. The paper claims that "bifunctionality is not a simple sum of two objectives," but does not include a "single-function AMP plus post hoc targeting filtering" control; it claims that target resolution can infer targets from scenarios, but does not include an ablation of "manually specified targets vs. scenario-inferred targets." The absence of these two controls leaves the "necessity of joint optimization" and the "non-substitutability of target resolution" at the level of claims (Page 2, Section 3.2).
Questions for authors
Q1. Could you add a comparison with at least one comparable agent framework (such as the public implementation/protocol of MAC-AMP or PABLO) under a unified predictor setting? If direct execution is not possible, could you provide a qualitative or quantitative protocol-level comparison? Q2. Could you conduct a "single-function AMP baseline plus post hoc targeting filtering" control to demonstrate the necessity of joint bifunctional optimization? Q3. In the caption of Figure 2, could the regions corresponding to (A), (B), (C), and (D) be labelled in the figure? Should the reference to "Fig. 1a" at the beginning of Section 2 be "Fig. 2"? Q4. Was the selection of second-function targets across the 26 scenarios validated by independent experts? Q5. What is the exact composition of the eight scenarios in the factorial experiment in Table 3? Do they cover both the structure-based and sequence-based paths, as well as host and pathogen targets?
3 comments
Q2. Joint Optimization versus Post-hoc Filtering
We thank the reviewer for this suggestion. We compare JANUS-PEP with an AMP-only baseline that optimizes MIC and HC50 without binding feedback during redesign. All generated candidates are subsequently evaluated using the same binding criterion. Both settings use the same starting peptides, prediction tools, and maximum candidate-evaluation budget (150 evaluations per scenario). The key difference is whether binding feedback is incorporated during iterative redesign.
| Method | Joint Success | MIC (µM) ↓ | HC50 (µM) ↑ | Binding Pass Rate |
|---|---|---|---|---|
| AMP-only + Post-hoc Binding Filter | 1/6 | 11.2 | 118.4 | 0.12 |
| JANUS-PEP (Joint) | 6/6 | 17.3 | 142.2 | 1.00 |
JANUS-PEP's binding pass rate is 1.00 by construction, since a candidate is delivered only when all three criteria hold. The column is included to make the difference between the two procedures visible rather than as a performance figure.
The results show that AMP-only optimization achieves a lower predicted MIC, but only 1/6 scenarios produce candidates satisfying all three criteria after binding filtering. In contrast, JANUS-PEP succeeds in 6/6 scenarios, with a higher predicted HC50.
These results highlight the importance of joint optimization. Improving antimicrobial potency and hemolytic safety alone does not guarantee target binding. Incorporating binding feedback during redesign helps the agent identify peptides that satisfy all three objectives. Together with Q1: existing frameworks optimize objectives that are given, and this control shows that even when all three objectives are given, satisfying them in sequence does not work.
Q3. Figure Labels and References
Thank you for identifying these issues. We will add the (A), (B), (C), and (D) labels to Figure 2 and correct the reference from "Fig. 1a" to "Fig. 2" in Section 2.
Q4. Validation of Second-Function Target Selection
No independent expert review was conducted for the 26 selected targets. Instead, target selection was performed by the Planner and supported by literature evidence and three validation gates: extracellular accessibility, mechanistic relevance (effector rather than correlate), and intervention precedent. Appendix C documents the biological rationale and supporting literature for each target, making the selection process traceable to published evidence rather than relying solely on model judgment.
We further evaluate the specificity of target selection in Table 5. Fifteen deliberately inappropriate targets from three failure categories were embedded in otherwise plausible scenarios. The system rejected 14 of the 15 targets. The single incorrectly admitted target was a disease correlate rather than a causal effector, suggesting that distinguishing effectors from correlates remains the more challenging criterion.
We acknowledge that literature-grounded selection and these validation gates do not replace independent expert assessment. We will explicitly state this limitation in the revised manuscript and identify independent expert review as an important direction for future validation, alongside experimental testing of the designed peptides.
Q5. Composition of the Eight Scenarios in Table 3
The factorial experiment uses eight scenarios from the 26 clinical cases, covering both design paths and host and pathogen targets.
| Scenario | Target | Second Function | Path | Target Type |
|---|---|---|---|---|
| S1 | TLR4 (O00206) | Endotoxin neutralization | Structure | Host |
| S2 | IL-1β (P01584) | Anti-inflammatory | Structure | Host |
| S4 | α-toxin (P0C216) | Anti-virulence | Structure | Pathogen |
| S5 | CagA (P55980) | Anti-virulence | Structure | Pathogen |
| Q2 | IL-17A (Q16552) | Immunomodulation | Sequence | Host |
| Q3 | Enterotoxin B (A7Y1W2) | Anti-toxin | Sequence | Pathogen |
| Q11 | MrkA (D5FKS5) | Anti-biofilm | Sequence | Pathogen |
| Q13 | Angiopoietin-2 (O15123) | Pro-angiogenic | Sequence | Host |
The set contains four structure-based and four sequence-based scenarios, with four host and four pathogen targets. It also covers seven distinct second-function labels.
All four experimental conditions use identical starting peptides, batch sizes, and round budgets. In the memory-off conditions, neither the page store nor the memory index is available to the agent during redesign. This controlled comparison isolates the effects of memory and Redesigner optimization under matched experimental settings.
I appreciate the authors’ response and the additional experiments. Using consistent predictors and a fixed 150-evaluation budget across all six test scenarios, JANUS-PEP successfully solves 6 out of 6 cases, versus 4 out of 6 for PABLO. It yields higher predicted HC50 (142.2 µM vs. 109.1 µM) and selectivity (8.2 vs. 6.9), though with a marginally higher MIC (17.3 µM vs. 15.8 µM). The post-hoc filtering control in Q2 helps isolate the contribution of the joint redesign framework. When optimizing potency and safety without binding feedback, the MIC drops to 11.2 µM, but the binding pass rate falls to 0.12, and overall joint success drops to just 1 out of 6 cases. Table 3’s breakdown of the eight scenarios confirms a balanced split by design paradigm (four structure-based, four sequence-based) and target category (four host, four pathogen). Adding (A-D) panel labels to Figure 2 and correcting the reference in Section 2 should address the remaining presentation issues.
My main remaining concern lies in the limited scope of external comparisons and independent validation. The budget-matched comparison against PABLO only covers six scenarios, and MAC-AMP does not incorporate a binding objective, making it a sequence-only baseline rather than a direct head-to-head comparator. As I noted in Q4, the 26 second-function targets were selected via literature-based criteria without independent expert review, and all candidate peptides generated are still at the computational prediction stage, with no wet-lab experimental validation. Although the internal benchmark results are consistent and well-controlled, the breadth of external validation against comparable design frameworks is still fairly limited.
Overall, the architectural design and empirical controls are sufficiently robust to support the paper’s core claims, provided the additional baselines, ablation studies, and discussion of limitations are included in the revised manuscript. I therefore maintain my original rating: Rating 3, Confidence 3
We thank the reviewer for the constructive feedback and for recognizing the novelty of scenario-grounded bifunctional peptide design. We appreciate the suggestions for strengthening the baseline comparisons and experimental validation. We address each question below.
Q1. Comparison with Existing Agent Frameworks
We thank the reviewer for this suggestion. JANUS-PEP has two stages: resolving the second function and its target from the infection scenario, and then optimizing one peptide against binding, potency and hemolysis jointly. MAC-AMP and PABLO address the second stage only, since both start from objectives the user fixes in advance, so the comparisons below hold the first stage fixed and compare the redesign loop.
PABLO under unified predictors. PABLO (Maus et al., 2026) is a general-purpose agentic black-box optimizer that supports custom objectives and constraints. We adapt it to our task without changing its core optimization framework. We use the same evaluators as JANUS-PEP: PyRosetta ΔΔG for structure-based binding, Boltz ipTM for sequence-based binding, APEX for MIC, and HemoPI2 for HC50.
Both methods use the same starting peptides, acceptance thresholds, and total candidate-evaluation budget (150 evaluations per scenario). We evaluate six scenarios, including three structure-based and three sequence-based cases. For PABLO, we minimize predicted MIC subject to the same binding and hemolytic safety thresholds used by JANUS-PEP. Both methods are evaluated using the same joint acceptance criteria. On the structure-based path, both methods operate on the same complex with a fixed backbone. Only amino acid substitutions are allowed.
MAC-AMP comparison. MAC-AMP (Zhou et al., ICLR 2026) optimizes antimicrobial activity, AMP likelihood, toxicity, and structural reliability. Its original framework targets bacterial species rather than specific protein-binding interfaces and does not directly include a receptor-binding objective.
We therefore evaluate an adapted version on antimicrobial activity and hemolytic safety. We replace its MIC predictor and ToxinPred 3.0 with APEX and HemoPI2 during optimization while retaining the remaining optimization framework. This ensures consistent activity and hemolysis evaluation.
Since MAC-AMP generates peptides de novo rather than editing a fixed starting peptide, we report it as a complementary reference rather than a matched-budget comparison.
MAC-AMP optimizes no binding objective, so the joint criterion is undefined for it.
JANUS-PEP delivers a passing candidate in all six scenarios and PABLO in four. With n=6 we do not read much into the gap itself. The point is that the two methods are in the same range on each individual axis, and separate on the joint criterion.
The MAC-AMP comparison provides a reference for sequence-only AMP optimization. It achieves lower predicted MIC but also lower HC50, highlighting the trade-off between antimicrobial potency and hemolytic safety. Unlike JANUS-PEP, this comparison does not assess target-specific binding.